RNAC- Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc. (RNAC) has 13 insiders with recent SEC Form 4 filings, including 17 buys and 9 sells. RNAC is classified in the Biotechnology industry within the Health Care sector.
Insider Ownership
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 8.65M | $75.74M | - | |
| 10% | 511.6K | $4.48M | - | |
| CEO | 323.5K | $2.83M | - | |
| CFO | 121.2K | $1.06M | - | |
| Other | 94.2K | $825.4K | - |
Activity
Buys and sells only
Transactions
10 filings
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 6, 2026 | Miljkovic Milos73 | Chief Medical Officer | Sell | 3,573 | $6.82 | $24,366.79 | -5.7% | -11.4% | - | |
| Jan 6, 2026 | Davis Blaine75 | Chief Financial Officer | Sell | 10,591 | $6.82 | $72,227.44 | -8.0% | -11.4% | - | |
| Jan 6, 2026 | Brunn Carsten86 | President And CEO | Sell | 23,766 | $6.82 | $162,076.99 | -6.8% | -11.4% | - | |
| Dec 4, 2025 | Barabe Timothy C49 | Director | Buy | 30,000 | $6.86 | $205,797.00 | +123.1% | +14.2% | - | |
| Apr 11, 2025 | Springer Timothy A49 | Director, 10% Owner | Buy | 149,075 | $10.21 | $1,522,517.04 | +0.3% | +26.9% | -44.0% | |
| Mar 20, 2025 | Springer Timothy A49 | Director, 10% Owner | Buy | 89,863 | $15.26 | $1,371,154.37 | +0.4% | -37.2% | -59.1% | |
| Jan 14, 2025 | Springer Timothy A49 | Director, 10% Owner | Buy | 20,967 | $17.47 | $366,353.71 | - | -27.9% | -57.6% | |
| Jan 6, 2025 | Kurtoglu Metin80 | Chief Technology Officer | Sell | 4,875 | $16.78 | $81,790.38 | -3.7% | -42.7% | -60.1% | |
| Jan 6, 2025 | Miljkovic Milos73 | Chief Medical Officer | Sell | 1,880 | $16.78 | $31,541.74 | -2.6% | -42.7% | -60.1% | |
| Jan 6, 2025 | English Emily | Chief Operations Officer | Sell | 1,797 | $16.78 | $30,149.19 | -2.2% | -42.7% | -60.1% |
Page 1Next →